Four States End Weight Loss Drug Coverage—What Happened Next Was Stark
Summary
California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage for GLP-1 drugs approved for weight loss on January 1, 2026. A study found that Medicaid-funded prescriptions for these drugs fell sharply in the four states compared with states that kept coverage, though it could not determine how many people stopped treatment or measure health outcomes.Key Facts
- The four states cited high drug costs as a reason for ending coverage.
- Researchers analyzed Medicaid State Drug Utilization Data from January 2022 through March 2026.
- In the four states, quarterly prescriptions fell from 2,914 to 421 per 100,000 Medicaid beneficiaries between the last quarter of 2025 and the first quarter of 2026.
- In 10 states that maintained coverage, the prescription rate fell from 3,006 to 2,758 per 100,000 beneficiaries over the same period.
- The study estimated that 175,500 to 526,600 fewer beneficiaries may have filled weight-loss GLP-1 prescriptions in the four states after coverage ended.
- The researchers counted prescriptions, not individual patients, and could not determine exactly how many people lost access to treatment.
- The study did not measure health outcomes or prescriptions paid for privately.
- A physician interviewed about the findings suggested that patients losing coverage ask clinicians about covered weight-management drugs, counseling, and structured programs.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.